Physician profile
Birgit H Amann
NPI 1386663789
$980,177.15
in general payments reported to CMS, 2019-2025
35 companies · $156K in 2025
The $156K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193K · 2020: $54K · 2021: $52K · 2022: $132K · 2023: $189K · 2024: $205K · 2025: $156K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $272K · Honoraria: $104K · Consulting Fee: $71K · Travel and Lodging: $55K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $271,729.75 |
| Honoraria | $104,015.00 |
| Consulting Fee | $70,501.00 |
| Travel and Lodging | $54,525.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,298.00 |
| Food and Beverage | $13,629.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $435,982.75 | 2019-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $186,678.84 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $83,647.79 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $54,901.14 | 2019-2025 | Rexulti |
| Corium, LLC | $41,105.55 | 2021-2025 | Azstarys, Azstarys |
| Noven Pharmaceuticals, INC. | $37,627.23 | 2023-2024 | Xelstrym |
| Axsome Therapeutics, INC. | $33,723.10 | 2023-2024 | Auvelity |
| Tris Pharma INC | $28,918.01 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Collegium Pharmaceutical, INC. | $27,504.56 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20,413.75 | 2022-2025 | |
| Adlon Therapeutics L.P. | $13,677.09 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $4,797.12 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $3,199.92 | 2019-2025 | Trintellix |
| Noven Therapeutics, LLC | $2,364.91 | 2024-2025 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $1,600.00 | 2025 | Relexxii |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $848.21 | 2019-2025 | Equetro, Raldesy |
| Lundbeck LLC | $608.36 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $433.80 | 2019-2020 | |
| Neos Therapeutics, Lp | $433.65 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Allergan, INC. | $374.02 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.60 | 2020-2025 | Caplyta |
| Alkermes, INC. | $207.96 | 2021-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $162.87 | 2020-2023 | Austedo, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $137.72 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $137.69 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $85.53 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $82.13 | 2025 | Fanapt |
| Shire North American Group INC | $67.36 | 2019 | |
| Owp Pharmaceuticals, INC. | $62.06 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $50.30 | 2023 | Quviviq |
| Livanova USA, INC. | $43.45 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.73 | 2019 | |
| Eisai INC. | $20.35 | 2021 | |
| Sage Therapeutics, LLC | $17.47 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birgit Amann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.